🔗 Share this article

As America continues making historic changes to its vaccination recommendations, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by casting doubt on Covid shots in the global health crisis and has zeroed in on potential deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Health officials had intended to unveil sweeping changes to the childhood vaccine schedule recently, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with much of the world with little proof for benefit. The planned update has been delayed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this calendar year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

In her initial statements, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

Høeg has no obvious background in pharmaceutical research, regulation or leadership, which has been standard for former heads of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Former heads of the center would “understand legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an immense workload at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the generic program approves numerous off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and each of these need to be supervised,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which oversees over 5,000 staff members. “It is a enormous administrative position, if you do it right,” Woodcock said.

Agency Reaction and Contentious Initiatives

In response to questions about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative said that the “concerns rely on inaccurate premises”.

“Her experience matches the duties of her job,” the representative said, citing the months Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the agency head's new fast-track approval initiative, a contentious one-day medication authorization process that allegedly concerned her former heads. “How are these medications being chosen for this expedited pathway? Who makes the decisions?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Documented Track Record on Vaccines

With immunizations, Dr. Høeg has a clearer, if problematic, history, critics said. She authored a analysis using unconfirmed public submissions to assess the rate of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming administration included revising rules for recently developed shots and discontinuing “non-essential” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She’s an thorough dogmatist who starts off with her beliefs and reverse-engineers to fit the evidence in a extremely deceptive, dishonest way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow contrarians, {like|